Estee Lauder's transformation progress is encouraging, but the rating remains Equal-weight
AI summary card
Estee Lauder's transformation progress is encouraging, but the rating remains Equal-weight
Morgan Stanley believes Estee Lauder's core business is recovering, with better innovation and improving trends in China and emerging markets, but it maintains a neutral stance because demand for prestige beauty, travel retail, and potential M&A risk keep it cautious.
- The company reiterated confidence in its FY26 guidance and its outlook for about 3%-5% organic sales growth in FY27; exposure to the Middle East and travel retail is about 2% of sales and is currently considered manageable.
- China has posted share gains for five consecutive quarters, with growth expanding from core brands such as La Mer and Estee Lauder to brands including TOM FORD, Jo Malone, and Le Labo.
- Emerging markets excluding China account for about 10% of sales, and the company’s long-term target is to raise that to more than 15%; India, Turkey, Southeast Asia, and the Middle East are the key incremental regions.
- U.S. business is improving sequentially, and expansion in Amazon, TikTok Shop, DTC, Sephora, and specialty retail channels is helping reduce dependence on the traditional department store channel.
- The company says it will have stronger M&A integration capabilities once the organizational structure and PRGP program are largely complete, but Morgan Stanley remains cautious about potential large acquisitions, especially Puig-related rumors.
Report interpretation
Overview
This report is Morgan Stanley's conference note on Estee Lauder Companies Inc following the Paris luxury conference. The core takeaway is that management is more confident in the Beauty Reimagined transformation, FY26 guidance, FY27 growth outlook, China recovery, online channel expansion, and emerging market growth; however, the analyst still maintains an Equal-weight rating because demand for prestige beauty, the pace of travel retail recovery, competitive pricing, and the execution risk of a potential large M&A remain concerns.
Core views
First, the core business recovery is progressing, and innovation, online penetration, China improvement, emerging market growth, sequential improvement in the U.S., and PRGP cost savings together support the transformation story. Second, the Middle East and travel retail risks after the Iran conflict currently appear manageable; the company disclosed related exposure of about 2% of sales and said a more flexible operating model can dynamically allocate resources across brands, channels, and regions. Third, the company believes the organization is ready to layer M&A, and even larger-scale acquisitions, on top of the core-business recovery, but the analyst remains skeptical about Puig-related rumors, which is also an important factor limiting an upgrade in the stock rating.
Analysis framework
The report is based primarily on a fireside chat with Estee Lauder President and CEO Stéphane de La Faverie and Nadine Graf, President of EMEA, UK & Ireland, and Emerging Markets, combined with the company's explanations of its FY26/FY27 outlook, regional sales trends, brand performance, channel reconfiguration, innovation cycle, PRGP savings, and valuation multiple. It takes a qualitative view and derives a $90 target price from about 22.5x FY28 EPS.
Methodology notes
Target price based on about 22.5x FY28 EPS
Morgan Stanley's $90 target price is based on about 22.5x FY28 EPS, reflecting EPS expansion from a low base, driven mainly by PRGP cost savings and margin recovery.
Beauty Reimagined and PRGP execution
The report assesses whether Estee Lauder's transformation is shifting from restructuring to growth by tracking China share gains, U.S. channel reconfiguration, online growth, shorter innovation cycles, cost savings, and organizational simplification.
Demand, travel retail, share, M&A, and competitive pricing
The analyst lists upside risks as stronger-than-expected China and travel retail, a rebound in category demand, continued share gains, and cost savings; and downside risks as weak prestige beauty demand, slower travel retail improvement, share reversals, Beauty Reimagined execution, and competitive pricing.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Estee Lauder Companies Inc (EL.US)Core coverage name
- Strengths
- China share has improved for five consecutive quarters, emerging market growth is faster than the global average, channel expansion across online and specialty retail is continuing, and PRGP savings and Beauty Reimagined should improve margins and innovation efficiency.
- Weaknesses
- The company is still in a transformation-repair phase, U.S. growth has not yet clearly returned to dollar share gains, and demand for prestige beauty and travel retail remains uncertain.
- Comparison
- Relative to the covered industry, Morgan Stanley assigns Equal-weight and sets the industry view at In-Line, indicating expected total returns roughly in line with the coverage universe average.
- Risks
- Less-than-expected execution of Beauty Reimagined, slower travel retail improvement, a renewed China recovery slowdown, competitive pricing pressure, and integration and financial risks from a potential Puig or other large M&A.
- China beauty marketKey growth and recovery driver
- Strengths
- Estee Lauder has gained share for five consecutive quarters, Hainan traffic and conversion have improved, Douyin penetration has expanded, and the China innovation center is accelerating localized innovation.
- Weaknesses
- Consumer confidence, as well as real estate and stock market improvement, may still fluctuate.
- Comparison
- China is described by management as a bright spot, with growth expanding from core brands to more brands.
- Risks
- A pullback in consumer confidence, heightened channel competition, or a slowdown in prestige beauty demand.
- Emerging markets excluding ChinaLong-term structural growth source
- Strengths
- Growth is 2-3x the global average, has already contributed profitable double-digit growth, and momentum in India, Turkey, Southeast Asia, and the Middle East is strong.
- Weaknesses
- Current sales contribution is still about 10%, and scaling requires continued channel and brand investment.
- Comparison
- The company’s long-term target is to raise the sales contribution to above 15%.
- Risks
- Geopolitics, foreign exchange, local consumption volatility, and execution complexity.
Key data
- Stock ratingEqual-weightMorgan Stanley maintains a relatively neutral rating.
- Industry viewIn-LineThe Household & Personal Care coverage view is In-Line.
- Target price$90.00Based on about 22.5x FY28 EPS.
- Current price$76.14Closing price on May 19, 2026.
- Implied upsideabout 18.2%Estimated from the $90.00 target price and the $76.14 close.
- Market cap$27,752 mmDisclosed in the chart, in millions of U.S. dollars.
- 52-week range$121.60–62.62Disclosed in the chart.
- FY27 organic sales growth outlookabout 3%-5%The company reaffirmed its preliminary FY27+ organic sales growth outlook.
- Middle East and travel retail exposureabout 2% of salesThe company believes the risk related to the post-Iran-conflict environment is currently manageable.
- China share performanceShare gains for five consecutive quartersGrowth has expanded from core brands to TOM FORD, Jo Malone, and Le Labo.
- Emerging market sales mixabout 10%, long-term target above 15%Emerging markets excluding China are driven by India, Turkey, Southeast Asia, and the Middle East.
- Innovation sales mixmid-to-high double-digit percentage, long-term target about 25%The company stresses that innovation must be accretive to gross margin.
Impact & implications
For investors, the conference note improves visibility into Estee Lauder's transformation: if improvements in China, the U.S., online channels, and emerging markets continue and PRGP savings are realized, EPS and margin recovery could support the target price; however, the Equal-weight rating shows the analyst still does not see the risk/reward as sufficiently asymmetric, especially given volatility in prestige beauty demand, uncertainty around travel retail recovery, competitive pricing, and the integration risk of a potential large acquisition.
Risks
- Demand for prestige beauty is weaker than expected.
- Travel retail recovery is slower than expected.
- Market share gains slow or reverse.
- Execution of Beauty Reimagined and PRGP falls short of expectations.
- Competitive pricing pressure intensifies.
- Potential large M&A, especially Puig-related rumors, could create integration and valuation risk.
- The Iran conflict and broader geopolitical volatility may affect Middle East and travel retail demand.
What to watch
- Whether FY26 guidance is met and whether the FY27 organic sales growth outlook of about 3%-5% is maintained.
- Approval of the PRGP plan, savings realization, and execution progress after FY27.
- China market share, Hainan traffic and conversion, Douyin penetration, and the pace of China-local innovation.
- U.S. retail sales share, the gap between shipments and retail sales, and the impact of channel expansion across Amazon, TikTok Shop, DTC, and Sephora.
- Whether emerging markets excluding China move from about 10% of sales toward the above-15% target.
- Whether the innovation sales mix can continue to rise from the mid-to-high double-digit range toward the about 25% target while still supporting gross margin improvement.
- Whether the company pursues large M&A and any price, financing, and integration path for a potential Puig deal.